General MedicationsINJECTIONStandard
ELZONRIS
TAGRAXOFUSP-ERZS
Standard Dose
1000MCG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview ELZONRIS is listed in Drugs@FDA under application 761116 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient TAGRAXOFUSP-ERZS Form and strength SOLUTION;INJECTION - 1000MCG Sponsor STEMLINE THERAPEUTICS INC Submission history Latest submission status date: 2023-07-26 00:00:00.
Structured Monograph
Clinical summary
Approval overview ELZONRIS is listed in Drugs@FDA under application 761116 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient TAGRAXOFUSP-ERZS Form and strength SOLUTION;INJECTION - 1000MCG Sponsor STEMLINE THERAPEUTICS INC Submission history Latest submission status date: 2023-07-26 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.